Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - A 617 400-patient study

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 8, 2012, Pages 790-799

  Valkhoff, V E ^a   Van Soest, E M ^a   Masclee, G M C ^a   De Bie, S ^a   Mazzaglia, G ^b   Molokhia, M ^c   Kuipers, E J ^a   Sturkenboom, M C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Italian College of General Practitioners   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARTHROTEC; CARBASALATE CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENERAL PRACTICE; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; STOMACH PROTECTION; TIME SERIES ANALYSIS; UNITED KINGDOM; UPPER GASTROINTESTINAL TRACT;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HUMANS; ITALY; LACTONES; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; SULFONES;

EID: 84866365307     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12028     Document Type: Article

References (29)

1. Lanza FL, Chan FK, Quigley EM,. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
2. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al,. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
3. Rostom A, Moayyedi P, Hunt R,. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29: 481-96.
4. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al,. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60: 1650-9.
5. Valkhoff VE, van Soest EM, Sturkenboom MC, Kuipers EJ,. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther 2010; 31: 1218-28.
6. Moore RA, Derry S, Phillips CJ, McQuay HJ,. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006; 7: 79.
7. Vonkeman HE, Fernandes RW, van de Laar MA,. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007; 45: 281-8.
8. van Dijk KN, ter Huurne K, de Vries CS, van den Berg PB, Brouwers JR, de Jong-van den Berg LT,. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002; 24: 100-3.
9. Boxel OS, Hagenaars MP, Smout AJ, Siersema PD,. Socio-demographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2009; 7: 855-61.
10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F, et al,. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 2001; 57: 737-43.
11. Garner SE, Fidan DD, Frankish R, Maxwell L,. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005; 1: CD005115.
12. European medicines agency public statement on the suspension of the marketing authorisation for bextra (valdecoxib) in the European union. 2005. Available at: http://www.panaceabiotec.com/Essential/35823405en-27.10.05.pdf. Accessed August 16, 2012.
13. European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines. 2007. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Press-release/2009/11/ WC500010995.pdf. Accessed August 16, 2012.
14. Thiebaud P, Patel BV, Nichol MB,. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health 2006; 9: 361-8.
15. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM,. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf 2008; 17: 9-19.
16. Valkhoff VE, van Soest EM, Mazzaglia G, Molokhia M, Schade R, Trifiro G, et al,. Adherence to gastroprotection during cyclooxygenase-2 inhibitor use and the risk of upper gastrointestinal events: a population-based study. Arthritis Rheum 2012; 64: 2792-802.
17. Lamberts H, Wood M, Hofmans-Okkes IM,. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 330-9.
18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Available at: http://www.whocc.no/atcddd/ . Accessed August 16, 2012.
19. World Health Organization. Classification of Diseases. Available at: http://www.who.int/classifications/icd/en/. Accessed August 16, 2011.
20. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al,. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10.
21. SPSS. SPSS Trends 14.0 User's Guide. Illinois: SPSS Inc, 2005.
22. Cavazos JM, Naik AD, Woofter A, Abraham NS,. Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study. Aliment Pharmacol Ther 2008; 28: 789-98.
23. Alacqua M, Trifiro G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al,. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008; 59: 568-74.
24. Usher C, Bennett K, Teeling M, Feely J,. Characterizing new users of NSAIDs before and after rofecoxib withdrawal. Br J Clin Pharmacol 2006; 63: 494-7.
25. Sun Shawn X, Lee Kwan Y, Bertram CT, Goldstein JL,. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007; 23: 1859-66.
26. Moens HJ, van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J, Numans ME,. Guideline 'NSAID use and the prevention of gastric damage'. Ned Tijdschr Geneeskd 2004; 148: 604-8.
27. National Institute for Clinical Excellence. Guidance on the use of Cyclo-Oxygenase (Cox) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthritis and Rheumatoid Arthritis. (Technology appraisal guidance 27). London: NICE (replaced by CG59 en CG 79). 2001.
28. Agenzia Italiana del Farmaco. Le note AIFA 2009: Una guida per l'uso appropriato dei farmaci. BIF 2009; 16: 195-7. Available at: http://www. paginesanitarie.com/note-aifa-definitivobif5-2009-10.pdf. Accessed April 4, 2012.
29. Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC,. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011; 33: 77-88.